ISI Group initiated its coverage on Henry Schein HSIC with an Underweight rating and a price target of $74.50.
ISI Group noted, "Our thesis for HSIC is based on the evolution of the business from a pure distributor to a value-added partner, the continuation of an active M&A strategy to support supplemental growth, and potential headwinds from the company's international business. We also view HSIC's premium valuation relative to the rest of the Healthcare Technology & Distribution group (excluding Health IT) as unwarranted given similar organic growth profiles (particularly when compared to the pharma distribution companies)."
Henry Schein closed at $78.55 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in